IDH1 and central nervous system cancer: Our results present evidence supporting a significantly better prognosis, TMZ treatment efficacy, and higher D-2HG level in IDH1-mutant gliomas compared to their IDH1 wild-type counterparts (Figs. 1, S1, and 2).